Company intelligence / Profile preview

Thrombolytic Science International

Cambridge, Massachusetts, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Phase 2

Overview

The company completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA/HisproUK dual regimen. Currently testing its dual regimen in a Phase 2 clinical trial in ischemic stroke patients. FDA cleared IND application for mutant prourokinase in September 2024. Following promising Phase II results from the DUMAS trial in stroke patients in the Netherlands, advancing to a Phase II trial in the UK for myocardial infarction following MHRA approval.

Therapeutic areas: HematologyCardiovascular
Modalities: EnzymeBiotherapyDual thrombolytic therapy
Industry: Biotech

Drug pipeline

3 assets

mutant pro-urokinase

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Thrombolytic Science International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrombolytic Science International.

Explore the full profile